Tag - CMND

Feature

Clearmind spearheading novel, life-changing psychedelic solutions for binge behaviors and mental health

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) is discovering and developing safe, novel psychedelic-derived therapeutic candidates with its new psychoactive molecule, 5-Methoxy-2-aminoindane (MEAI), to address widespread...

November 26, 2024

Developments

Clearmind receives IRB approval for trial of CMND-100 for AUD at second clinical site

Clearmind Medicine (NASDAQ:CMND) has announced that it has received Institutional Review Board (IRB) approval from one of its U.S. clinical sites for part A of its Phase I/IIa clinical trial of CMND-100 for the...

October 10, 2024

Developments

Clearmind files additional U.S. patent application for MEAI to treat obesity

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced it has filed an additional patent application with the USPTO for the novel proprietary composition of its MEAI compound for treating metabolic syndrome and obesity...

July 16, 2024

Tag - CMND

Clearmind spearheading novel, life-changing psychedelic solutions for binge behaviors and mental health

Clearmind receives IRB approval for trial of CMND-100 for AUD at second clinical site

Clearmind files additional U.S. patent application for MEAI to treat obesity

General

More